CENSURATO DA FACEBOOK

 MODERN SCIENCE 

Who owns Moderna and where is the company based?

• Chiara Fiorillo

• 16 Nov 2020, 14:55
• Updated: 16 Nov 2020, 16:17

MODERNA announced encouraging news about its Covid-19 vaccine on Monday, November 16.

Trials on more than 30,000 people found that only five who were given the jab developed the virus – none of them with severe symptoms.

⚠️ Read our coronavirus live blog for the latest news & updates

6

Moderna's coronavirus vaccine was 94.5% effective, the company saidCredit: Reuters

Who owns Moderna?

Biotech company Moderna was founded in 2010 and was formerly named ModeRNA Therapeutics.

The company is part of the US government's Operation Warp Speed programme.

It is owned by shareholders.

Noubar Afeyan is co-founder and chairman of Moderna

6

Moderna is located in Cambridge, MassachusettsCredit: Reuters

Where is Moderna located?

Moderna is based in Cambridge, Massachusetts.

Its headquarters are at 200 Technology Square, Cambridge.

6

Stéphane Bancel is the CEO of ModernaCredit: Getty Images - Getty

Who is the CEO of Moderna?

Stéphane Bancel has been the Chief Executive Officer of Moderna since 2011.

The French businessman is also 9 per cent owner of Moderna.

6

Moderna's vaccine trial involved 30,000 peopleCredit: AP:Associated Press

What other medicines and vaccines does Moderna produce?

Moderna's medicines include development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas.

It uses mRNA to spur the body to produce its own therapeutic proteins.

Moderna calls mRNA “the software of life”.

6

Only five of the participants in the trial developed the virusCredit: Twitter

How effective is the Moderna Covid vaccine and when will it be available?

Moderna has said its vaccine was 94.5 per cent effective in preventing Covid-19 based on interim data from a late-stage clinical trial.

"We are going to have a vaccine that can stop Covid-19," Moderna President Stephen Hoge said in a telephone interview.

Moderna expects to be able to produce 20 million doses by the end of the year, and between 500 million and 1 billion in 2021.